Kymera Therapeutics, Inc. (KYMR)

On our desk, KYMR's Q2 2026 print was a clean beat. Collaboration revenues jumped to $65 million, thanks to a $45 million option exercise fee from Gilead Sciences for KT-200 and a $20 million milestone from Sanofi. With a net loss narrowing to $61.21 million and cash reserves hitting $1.5 billion, the balance sheet is locked down with a projected runway into 2029. Year-to-date shares have surged 35.6%, significantly outperforming the broader biotech index.

From a clinical protocol standpoint, the biggest news is that KT-621 (STAT6) BROADEN2 Phase 2b atopic dermatitis trial completed enrollment nearly six months ahead of schedule. Investigator enthusiasm is sky-high given the massive unmet need for an oral therapy in a market where only a single-digit percentage of moderate-to-severe AD patients use advanced systemics. Data is slated for year-end 2026, setting up a major binary catalyst.

Watching the macro trade, we noted RBC's downgrade to neutral back on July 13, pointing out that the oral STAT6 degrader thesis has largely re-rated following early BROADEN2 enrollment metrics and read-throughs from AbbVie-Apogee's $10.9B deal. While the fundamentals look stellar, some smart money desks view this as a maturing, stretched theme that might be better accumulated on a pullback to the $100 shelf rather than chased right into the late 2026 catalyst gap.

As a pipeline analyst reviewing the broader portfolio, it's not just about KT-621. The KT-621 BREADTH Phase 2b asthma trial is ongoing with data expected in late 2027, Phase 3 trials in AD are planned to kick off by mid-2027, the KT-579 (IRF5) healthy volunteer trial will post data in Q4 2026, and Sanofi has commenced a Phase 1 trial for KT-485 (IRAK4) in healthy volunteers and HS patients. The platform breadth is delivering multiple near-term catalysts.

Looking at the options desk, implied volatility is pricing in a significant move as we approach the year-end 2026 topline data readout for KT-621. RandD expenses did ramp up to $119.5 million from $78.4 million last year, reflecting intensive clinical execution. However, the top-line beat—posting a loss of 62 cents per share versus the consensus estimate of 64 cents—cushions near-term sentiment and provides stability against broader market drawdowns.